Document is current
Any future updates will be listed below
-
Authors
Chakraborty, Samarpana
Shapiro, Lauren C.
de Oliveira, Sofia https://orcid.org/0000-0003-0893-111X
Rivera-Pena, Bianca https://orcid.org/0000-0001-8821-0210
Verma, Amit https://orcid.org/0000-0001-7592-7693
Shastri, Aditi https://orcid.org/0000-0002-5366-8288
- License Information
-
More Information
Article History
Received: 11 April 2021
Revised: 16 July 2021
Accepted: 22 July 2021
First Online: 14 September 2021
Competing interests
: The authors declare no competing interests. A.S. has received research funding from Kymera Therapeutics, Consulting fees from GLG & Guidepoint & honoraria from OncLive. A.V. has received research funding from BMS, Jannsen, MedPacto, Novartis, Curis, Prelude, and Eli Lilly and Company, has received compensation as a scientific advisor to Novartis, Stelexis Therapeutics, Acceleron Pharma, and Celgene, and has equity ownership in Throws Exception and Stelexis Therapeutic.
